In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

Barboval - a combined drug whose therapeutic effect is due to the pharmacological properties of its components.

Ethyl α-bromisovalerianic acid has a reflex, calming and antispasmodic effect, due to a decrease in reflex excitability in the central nervous system and an increase in the inhibition of neurons in the cortex and subcortical structures of the brain, as well as a decrease in the activity of central vasomotor centers and local direct antispasmodic effect on smooth the muscles.

Phenobarbital suppresses the activating effect of the centers of the reticular formation of the middle and medulla oblongata on the cerebral cortex, thereby reducing the flow of stimulating effects on the cerebral cortex and subcortical structures. The decrease in activating effects has (depending on the dose) a calming, tranquilizing and hypnotic effect. Barboval reduces the stimulating effect on the vasomotor centers, coronary and peripheral vessels, reducing the total blood pressure, eliminating and preventing spasms of blood vessels, especially cardiac.

Menthol in menthyl ester of isovalerianic acid has a calming effect on the central nervous system, slows the peristalsis of the stomach and intestines, reduces flatulence, and also has a moderate reflex vasodilator and antispasmodic effect.


Neurosis accompanied by increased excitability, insomnia, hysteria; as part of the complex treatment of lung attacks of angina pectoris, initial stage ag, tachycardia of functional genesis, with spasms of the stomach and intestines, flatulence.


It was taken orally with a small amount of liquid or on a piece of sugar under the tongue.

Doses and duration of treatment are determined by the doctor individually. Usually adults take 10-15 drops 2-3 times a day for 10-15 days.

It is better to take the drug 20-30 minutes before eating.

After a break of 10-15 days, the course of treatment can be repeated.


Hypersensitivity to any components of the drug, liver and kidney failure, liver porphyria, severe heart failure, severe arterial hypotension, acute myocardial infarction, diabetes mellitus, depression, myasthenia gravis, alcoholism, drug and drug dependence, respiratory diseases with shortness of breath, obstructive syndrome .

Side effects

Usually the drug is well tolerated. possible development of the following adverse reactions:

from the digestive system: constipation, a feeling of heaviness in the epigastric region, with prolonged use - impaired liver function, nausea, vomiting;

from the nervous system: weakness, ataxia, impaired coordination of movements, nystagmus, hallucinations, paradoxical agitation, decreased concentration of attention, fatigue, slowed down reactions, headache, cognitive impairment, confusion, drowsiness, lightheadedness;

from the hemopoietic organs: anemia, thrombocytopenia, agranulocytosis;

from the cardiovascular system: arterial hypotension, bradycardia; from the immune system: hypersensitivity reactions, including angioedema, allergic reactions including skin rash, itching, urticaria;

on the part of the skin and mucous membranes: Stevens-Johnson syndrome, toxic epidermal necrolysis;

from the musculoskeletal system: with prolonged use of drugs containing phenobarbital, there is a risk of violation of osteogenesis;

other: shortness of breath.

Prolonged use of preparations containing bromine can lead to bromine poisoning, which is characterized by the following symptoms: depression of the central nervous system, depressive mood, confusion, ataxia, apathy, conjunctivitis, rhinitis, lacrimation, acne or purpura.

special instructions

The presence of phenobarbital in the drug may lead to a risk of developing Stevens-Johnson and Lyell syndrome, which is most likely in the first weeks of treatment.long-term use is not recommended due to the risk of drug dependence, the possible accumulation of bromine in the body and the development of bromine poisoning. in cases where pain in the heart does not go away after taking the drug, you must consult a doctor to exclude acute coronary syndrome. the drug should be carefully prescribed for arterial hypotension, hyperkinesis, hyperthyroidism, adrenal hypofunction, acute and persistent pain, acute drug intoxication.

Use during pregnancy or breastfeeding. The drug should not be used by women during pregnancy or lactation.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. The drug can cause drowsiness and dizziness, therefore, during the treatment period, patients are not recommended to work with dangerous mechanisms and drive vehicles.

Children. There is no experience with the drug for the treatment of children, so it is not used in pediatric practice.


The simultaneous use with antipsychotics and tranquilizers potentiates, and with CNS stimulants, it weakens the effect of each component of the drug. barbovar, containing derivatives of barbituric acid, enhances the action of local anesthetics, analgesics and hypnotics. alcohol enhances the effects of the drug and may increase its toxicity. the effect of the drug is enhanced by the use of valproic acid preparations. the presence of phenobarbital in barbova can induce liver enzymes, and this makes its simultaneous use with drugs that are metabolized in the liver (with coumarin derivatives, griseofulvin, glucocorticoids, oral contraceptives, cardiac glycosides, antimicrobial, antiviral, antifungal, psychotropic, oral hypoglycemic, hormonal, immunosuppressive, cytostatic, antiarrhythmic, antihypertensive drugs, etc.), since their effectiveness will decrease as a result of a higher level of metabolism. MAO inhibitors prolong the effect of phenobarbital. rifampicin may decrease the effect of phenobarbital.

With the simultaneous use of phenobarbital with gold preparations, the risk of kidney damage increases.

With prolonged simultaneous use of phenobarbital with NSAIDs, there is a risk of gastric ulcer and bleeding.

The simultaneous use of phenobarbital with zidovudine enhances the toxicity of both drugs.

The drug increases the toxicity of methotrexate. While taking the drug should avoid drinking alcohol.


With prolonged or frequent use, cumulation of the drug may occur, which leads to clinical manifestations of an overdose, namely:

  • CNS depression, which is eliminated by the use of CNS stimulants (caffeine, cordiamine, etc.);
  • nystagmus, ataxia, decreased blood pressure, abnormalities in the blood formula.

Manifestations of chronic bromine poisoning are depression, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, impaired coordination of movement. To eliminate these manifestations, symptomatic therapy is prescribed.

The constant long-term use of the drug can be addictive, drug dependence, withdrawal symptoms, and a sudden cessation of use - withdrawal syndrome. Long-term use of the drug is sometimes accompanied by an increase in psychodynamic activity instead of the expected sedation.

Symptoms of an overdose: respiratory depression, up to its stop; depression of the central nervous system, up to coma; inhibition of cardiovascular activity, including rhythm disturbances, a decrease in blood pressure, up to the collapse state; nausea, weakness, decreased body temperature, decreased diuresis.

The treatment is symptomatic.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.

Tags: Barboval